KEEP BUT DO NOT DISPLAY

MannKind will get 35% of the profits while Sanofi is set to get 65% of profits on Afrezza. Afrezza was approved with a black box warning which states, "Acute bronchospasm has been observed in patients with asthma and COPD using Afrezza. Afrezza is contraindicated in patients with chronic lung disease such as asthma …

Swiss scientists have created an implantable molecular device with a sensor that measures blood pH levels and a gene feedback mechanism that produces the necessary amount of insulin if acidosis becomes a risk for type 1 diabetes patients. The molecular device was designed using various genes and proteins, and comprises a …

In a study using data from 5 million patients, researchers found that obese or overweight individuals had a higher risk of developing 10 common cancers. Leukemia and cancers of the uterus, gallbladder, kidney, cervix and thyroid rose linearly along with weight. Higher BMI was associated with a greater risk of …

A study found short bursts of fast walking resulted in better blood glucose control than did walking at a steady pace. Data on participants aged 57 to 61 revealed that only the interval walkers achieved a reduction in glucose levels at four months, while the control group and those who …

Men showed slightly greater hip-bone loss at four years than did those in the diabetes support and education cohort. However, researchers did not observe a similar trend in women with diabetes. The trial randomized 1,309 overweight and obese individuals with type 2 diabetes to an intensive lifestyle intervention (ILI) versus …

After revascularization procedures, the risk for total mortality, cardiovascular mortality and myocardial infarction is highest among patients with low BMI, according to research. Similarly, CV mortality was lowest among overweight patients in the meta-analysis conducted by Abhishek Sharma, MD, of the Maimonides Medical Center, Brooklyn, N.Y., and colleagues, who looked …

Diabetes Drug Empagliflozin (Jardiance- SGLT-2) Wins FDA Approval. More news in next week’s issue. GSK’s Tanzeum (GLP-1 agonist) is now available in pharmacies in the U.S.

Women who ate 5 grams daily of green-plant membranes purified from spinach lost more weight and had fewer urges to eat unhealthy foods than did those given a placebo, Swedish researchers reported. Women who consumed green-plant membranes also had higher secretions of the satiety hormone GLP-1. Green-plant membranes slow fat …

Xultophy, a type 2 diabetes candidate, received a positive opinion from the European Medicines Agency’s Committee. Xultophy is a once-daily single injection combination of insulin degludec and liraglutide. The CHMP recommended the approval of Xultophy for the treatment of adults suffering from type 2 diabetes in combination with glucose-lowering oral …

An analysis in the American Journal of Clinical Nutrition says replacing full-calorie foods and drinks with those using lower-calorie sweeteners resulted in modest improvements in BMI. The findings suggest that using lower-calorie sweeteners may boost adherence to weight-management initiatives. American Journal of Clinical Nutrition, July 2014